OA12101A - Antipicornaviral compounds and compositions, theirpharmaceutical uses, and materials for their synt hesis. - Google Patents

Antipicornaviral compounds and compositions, theirpharmaceutical uses, and materials for their synt hesis. Download PDF

Info

Publication number
OA12101A
OA12101A OA1200200160A OA1200200160A OA12101A OA 12101 A OA12101 A OA 12101A OA 1200200160 A OA1200200160 A OA 1200200160A OA 1200200160 A OA1200200160 A OA 1200200160A OA 12101 A OA12101 A OA 12101A
Authority
OA
OAPI
Prior art keywords
group
pharmaceutically acceptable
compound
substituted
heterocycloalkyl
Prior art date
Application number
OA1200200160A
Other languages
English (en)
Inventor
Peter S Dragovich
Thomas J Prins
Ru Zhou
Johnson Theodore O Jr
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of OA12101A publication Critical patent/OA12101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200200160A 1999-12-03 2000-12-01 Antipicornaviral compounds and compositions, theirpharmaceutical uses, and materials for their synt hesis. OA12101A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16898699P 1999-12-03 1999-12-03
US19205200P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
OA12101A true OA12101A (en) 2006-05-04

Family

ID=26864652

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200160A OA12101A (en) 1999-12-03 2000-12-01 Antipicornaviral compounds and compositions, theirpharmaceutical uses, and materials for their synt hesis.

Country Status (31)

Country Link
US (1) US6514997B2 (pl)
EP (1) EP1252145A1 (pl)
JP (1) JP2003515591A (pl)
KR (1) KR20020058076A (pl)
CN (1) CN1402710A (pl)
AP (1) AP2002002510A0 (pl)
AR (1) AR030540A1 (pl)
AU (1) AU777943B2 (pl)
BG (1) BG106754A (pl)
BR (1) BR0016742A (pl)
CA (1) CA2392504A1 (pl)
CO (1) CO5261566A1 (pl)
CZ (1) CZ20021906A3 (pl)
DO (1) DOP2000000108A (pl)
EA (1) EA200200625A1 (pl)
EE (1) EE200200281A (pl)
HK (1) HK1052933A1 (pl)
HU (1) HUP0204006A3 (pl)
IL (1) IL149427A0 (pl)
IS (1) IS6378A (pl)
MX (1) MXPA02005124A (pl)
NO (1) NO20022589L (pl)
NZ (1) NZ518934A (pl)
OA (1) OA12101A (pl)
PA (1) PA8507801A1 (pl)
PE (1) PE20020157A1 (pl)
PL (1) PL356062A1 (pl)
SK (1) SK7602002A3 (pl)
UY (1) UY26465A1 (pl)
WO (1) WO2001040189A1 (pl)
YU (1) YU40002A (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003159T2 (tr) 1998-04-30 2001-09-21 Agouron Pharmaceuticals,Inc. Antipicornaviral bileşikler, hazırlanışları ve kullanımları
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
WO2001096297A2 (en) * 2000-06-14 2001-12-20 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
DE60139506D1 (de) * 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
US7037911B2 (en) * 2002-06-26 2006-05-02 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors
WO2004078261A1 (en) * 2003-03-07 2004-09-16 The University Court Of The University Of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
AU2004312547A1 (en) * 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
US7462594B2 (en) * 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
US7087622B2 (en) 2004-05-07 2006-08-08 Janssen Pharmaceutica N.V. Pyridone compounds as inhibitors of bacterial type III protein secreation systems
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((s)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
AU2009285584B2 (en) * 2008-08-29 2015-04-02 Treventis Corporation Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
US11021513B2 (en) 2016-05-13 2021-06-01 Emory University Peptidomimetics for the treatment of norovirus infection
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN115667209A (zh) * 2020-04-23 2023-01-31 普渡研究基金会 用于治疗sars的化合物
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
CA2215211A1 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
ES2242225T3 (es) * 1996-05-14 2005-11-01 Agouron Pharmaceuticals, Inc. Inhibidores de proteasas 3c antipicornavirales y procedimientos correspondientes de utilizacion y de preparacion.
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
DK0975588T3 (da) * 1997-03-28 2004-01-12 Agouron Pharma Antipicornavirale forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
TR200003159T2 (tr) 1998-04-30 2001-09-21 Agouron Pharmaceuticals,Inc. Antipicornaviral bileşikler, hazırlanışları ve kullanımları
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
JP2003506457A (ja) 1999-08-04 2003-02-18 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗ピコルナウィルス化合物及び組成物、その医薬的使用、並びにその合成のための物質
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
CN1157391C (zh) 1999-08-24 2004-07-14 阿古龙制药有限公司 制备异噁唑甲酰胺及其类似物的方法和中间体

Also Published As

Publication number Publication date
BG106754A (bg) 2003-07-31
US6514997B2 (en) 2003-02-04
CA2392504A1 (en) 2001-06-07
EP1252145A1 (en) 2002-10-30
AR030540A1 (es) 2003-08-27
HUP0204006A2 (hu) 2003-03-28
UY26465A1 (es) 2001-06-29
US20010047006A1 (en) 2001-11-29
AP2002002510A0 (en) 2002-06-30
CN1402710A (zh) 2003-03-12
CO5261566A1 (es) 2003-03-31
EE200200281A (et) 2003-06-16
HK1052933A1 (zh) 2003-10-03
YU40002A (sh) 2006-01-16
EA200200625A1 (ru) 2002-12-26
SK7602002A3 (en) 2003-02-04
KR20020058076A (ko) 2002-07-12
IL149427A0 (en) 2002-11-10
NO20022589L (no) 2002-07-31
PA8507801A1 (es) 2002-08-26
AU777943B2 (en) 2004-11-04
NZ518934A (en) 2003-11-28
JP2003515591A (ja) 2003-05-07
NO20022589D0 (no) 2002-05-31
AU1809401A (en) 2001-06-12
MXPA02005124A (es) 2003-01-28
HUP0204006A3 (en) 2004-11-29
BR0016742A (pt) 2002-09-03
PE20020157A1 (es) 2002-02-22
PL356062A1 (pl) 2004-06-14
CZ20021906A3 (cs) 2003-02-12
IS6378A (is) 2002-05-10
WO2001040189A1 (en) 2001-06-07
DOP2000000108A (es) 2003-03-15

Similar Documents

Publication Publication Date Title
KR102866916B1 (ko) Lpa 수용체 길항제 및 이의 용도
US6514997B2 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
JP4212358B2 (ja) Vla−4阻害薬
US20230271973A1 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN114728168A (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TW201823208A (zh) N-醯基胺基酸化合物及其使用方法
RS67682B1 (sr) Jedinjenja ciklopropil-amida kao dvostruki inhibitori lsd1/hdac
WO1998018794A1 (en) Novel heterocyclic amide compounds and medicinal uses thereof
TWI820266B (zh) 巨環化合物及其用途
IL304110B2 (en) Inhibitors of keap1-nrf2 protein-protein interaction
CA2326763A1 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and methods for their synthesis
KR20220141331A (ko) P2x3 조정제
TW202300144A (zh) 抗病毒雜環化合物
TW202200565A (zh) 抗病毒性1,3-二氧代茚化合物
JPWO2005121135A1 (ja) Vla−4阻害薬
CN113015736B (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
HK40077288A (en) Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
HK1263406B (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
HK1060726B (zh) Vla-4抑制剂